Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|13|2|180-200

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.13, Iss.2, 2013-01, pp. : 180-200

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD)

By Zoccali Carmine   Mallamaci Francesca   Tripepi Giovanni  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 1, 2006-02 ,pp. : 131-135

Springer Publishing Company

Access to resources Recommend Favorite

Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study

By Lenzen Henrike   Tsikas Dimitrios   Böger Rainer  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 1, 2006-02 ,pp. : 45-49

Springer Publishing Company

Access to resources Recommend Favorite

The synthesis and metabolism of asymmetric dimethylarginine (ADMA)

By Leiper James   Vallance Patrick  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 1, 2006-02 ,pp. : 33-38

Springer Publishing Company

Access to resources Recommend Favorite

The Role of Asymmetric Dimethylarginine (ADMA) and Leptin in Hypertensive Patients

By Atamer A   Ilhan N   Kocyigit Y   Toprak G   Ozbay M   Celik Y  

The Journal of International Medical Research, Vol. 36, Iss. 1, 2008-01 ,pp. : 54-62

Field House Publishing

Access to resources Recommend Favorite

Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of angiogenesis

By Cooke John  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 1, 2006-02 ,pp. : 115-121

Springer Publishing Company

Access to resources Recommend Favorite